The FDA Just Approved a Long-Lasting Injection to Prevent HIV

US food and the drug management only confirmed a lenacapavir, injectable form Hiv About 100 percent is effective and prevention of only two doses per year. Science The magazine described the drug The most important scientific advance 2024.

In clinical trials, Lenacapavir proved 99.9 percent effective to prevent HIV infection in people who weighing more than 35 kilograms. Medicines, an antiretrovir, stimulating the immune reaction, but during the early stages of the HIV, violating the function of the virus, violating the covet of the virus, hinding the reproduction. This happens so much as the body receives injections every six months.

Lenacapavir has already been approved in some countries as a treatment in people with other treatment of HIV, which is in viral forms. However, before this week, its preventive use, the decision of the FDA has not been approved in an important new development in the fight against the HIV / AIDS epidemic.

The drug is not the first drug to protect against a HIV infection: pre-exposure prevention (preparatory) pills, including in many countries in the United States. However, these should be taken every day and make sure that these drugs should ensure continuous access and remember to take them. It is a known problem. Lenacapavir hopes that the long-term effects will facilitate the protection against the virus.

According to the Creator, Gilead Sciences, Lenacapavir Yeztugo will be sold under the name of trade. The company is committed to the production of 10 million doses in 2026.

“This is a historic day in the fight against HIV for decades. Yeztugo is one of our most important scientific advances in our time and offers a very real opportunity to help put an end to the HIV epidemic,” Daniel O’Day, Gilead and Gilead’s CEO statement Wednesday.

However, Lenacapavir may have an obstacle to get the price. Yeztugo will be the annual list of the annual list per capita in the United States. HIV / AIDS (UNAIDS) There is also the Executive Director of the United Nations Program Winnie Byanyima flag in the past It is unavailable for the fact that the drug is unavailable for many people in Africa, the biggest impact of the drug here. About two-thirds People living with HIV live in Africa living in Africa.

Gilead said Last year statement To Lenacapavir, “the company has developed a strategy to develop a strategy to allow large and sustainable access, although the company has not yet given a detailed information. An option can be “Volunteer licensing”, where other companies are allowed to produce and sell general versions of patented products in certain (often low-income) countries. Researchers at the University of Liverpool in England calculated One-yearly Lenacapavir’s value can be made up to $ 25 for a period.

This story originated first String in Spanish and has been translated from Spanish.